Jason Pitofsky insider trades: Regeneron Pharmaceuticals (REGN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | REGN | ↓ Sell | 3,883 | $941.79 | $3.7M | Direct | Nov 6, 2026 (2d) |
| Nov 4, 2026 | REGN | ↓ Sell | 179 | $950.76 | $170K | by Spouse | Nov 6, 2026 (2d) |
| Nov 7, 2025 | REGN | ↓ Sell | 431 | $651.43 | $281K | Direct | Nov 10, 2025 (3d) |
| Aug 7, 2024 | REGN | ↓ Sell | 487 | $1070.00 | $521K | Direct | Aug 7, 2024 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other REGN insiders
Open-market trades in the last 12 months
About Jason Pitofsky's insider trades
Jason Pitofsky is SVP Controller at Regeneron Pharmaceuticals (REGN). Since Aug 7, 2024, Jason has reported no open-market purchases and 4 sales worth $4.6M on SEC Form 4. In the last 12 months: 3 sales ($4.1M).
Their filings also include shares withheld for taxes (3 filings), option exercises (2 filings), grants and awards (2 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every REGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.